iRhythm Technologies is transforming from a cardiac patch maker into a full cardiac monitoring platform by integrating software and workflow solutions. In Q2 2026, the company posted 20.1% revenue growth, improved gross margin to 72.8%, and expanded adjusted EBITDA margin to 19.3%, raising its full-year outlook and achieving record free cash flow. The FDA-cleared ZEUS platform cuts clinician review time by half and aims to save $100 million over five years. The acquisition of VitalConnect broadens iRhythm's capabilities into mobile cardiac telemetry and remote monitoring, supporting margin goals for 2027 but also bringing integration and capital risks.
Wall Street upgrades Google as the most compelling tech stock among Apple and Broadcom due to its strong AI-driven growth, attractive valuation, and cloud business momentum. Google's Q2 revenue rose 24% to $119.8 billion with cloud growth acceleratin...
LivePerson has extended the deadline for stockholders to vote on its proposed merger with SoundHound AI to September 1, 2026, ahead of a special meeting on September 2. Over 97% of votes cast so far support the deal, which offers a 22% premium per sh...
Reese's has partnered with The Nitro Bar to create the Reese's Pumpkins PB Whip Latte, a limited-time fall drink inspired by the iconic chocolate and peanut butter flavors of Reese's Pumpkins candy. This unique coffee offering is available first at a...
Homerun Resources has signed a Memorandum of Understanding with Cebrace Cristal Plano, Brazil's largest float glass manufacturer, to explore a strategic commercial partnership for its solar glass facility in Bahia. Under this partnership, Cebrace wou...
Edelman Financial Engines, managing $326 billion in assets, disclosed a $34 million investment in Bitcoin ETFs, surpassing its $25 million stake in Amazon. This move highlights increasing institutional interest in Bitcoin through regulated ETFs, offe...
